Adaptive Biotechnologies Raises MRD Outlook After Q3 Profit
Adaptive Biotechnologies reported third-quarter results on November 4, 2026, posting net income of $2.8 million and raising its full-year outlook for minimal residual disease (MRD) revenue as clonoSEQ test volume and core MRD revenue grew sharply. The company now expects full-year 2026 MRD revenue of $276 million to $286 million, up from $268 million to $278 million, representing projected annual growth of 30% to 35%. Its expense outlook calls for approximately $350 million of total-company…